ASX-listed AFT Pharmaceuticals has expanded its therapeutics range with a new dry eye therapy containing Omega-3.
The company has introduced NovaTears +Omega-3, which is now available in addition to the existing Pharmaceutical Benefits Scheme-listed NovaTears. German firm Novaliq manufactures the therapies.
Since 2018, NovaTears sales have increased year-on-year for AFT. The preservative-free therapy is a lipid layer stabiliser targeted at evaporative dry eye sufferers.
According to the company, NovaTears +Omega-3 is a unique eye lubricant and tear film stabiliser in a multi-dose bottle, also designed for the relief of evaporative dry eye disease and meibomian gland dysfunction.
It combines high quality and highly concentrated Omega-3 fatty acids of algae origin and Perfluorohexyloctane.
NovaTears +Omega-3 is also said to spread quickly and easily on the eye with a long-lasting effect; and provides enhanced lubrication and protection for dry and irritated eyes.